Canada Pension Plan Investment Board reduced its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 40.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 224,139 shares of the biopharmaceutical company’s stock after selling 151,400 shares during the quarter. Canada Pension Plan Investment Board owned about 0.10% of Incyte worth $13,953,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Incyte by 4.0% in the 1st quarter. BlackRock Inc. now owns 20,635,865 shares of the biopharmaceutical company’s stock valued at $1,491,354,000 after acquiring an additional 798,475 shares during the period. Royal Bank of Canada increased its holdings in shares of Incyte by 117.4% during the first quarter. Royal Bank of Canada now owns 7,682,752 shares of the biopharmaceutical company’s stock worth $610,164,000 after purchasing an additional 4,148,559 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Incyte by 22.6% during the first quarter. Renaissance Technologies LLC now owns 5,602,433 shares of the biopharmaceutical company’s stock worth $404,888,000 after purchasing an additional 1,034,200 shares during the period. Geode Capital Management LLC increased its holdings in shares of Incyte by 2.4% during the first quarter. Geode Capital Management LLC now owns 3,961,742 shares of the biopharmaceutical company’s stock worth $285,676,000 after purchasing an additional 93,329 shares during the period. Finally, Pictet Asset Management SA increased its holdings in shares of Incyte by 168.8% during the first quarter. Pictet Asset Management SA now owns 2,216,141 shares of the biopharmaceutical company’s stock worth $160,161,000 after purchasing an additional 1,391,714 shares during the period. 92.61% of the stock is owned by institutional investors.
Incyte Price Performance
INCY stock opened at $54.98 on Thursday. The company has a quick ratio of 3.86, a current ratio of 3.91 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $57.32 and its 200 day simple moving average is $61.47. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of 29.09, a PEG ratio of 0.93 and a beta of 0.72. Incyte Co. has a 12-month low of $50.27 and a 12-month high of $86.29.
Analysts Set New Price Targets
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
- Five stocks we like better than Incyte
- How to Invest in Casino Stocks
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Dividend Tax Calculator
- 5 reasons TJX Companies will hit new highs in 2024
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.